The Pacific Northwest Dementia and Aging (PANDA) Neuropathology (NP) Group is a successful cooperative effort between the Alzheimer's Disease (AD) Center at Oregon Health &Science University (OHSU) and the AD Research Center (ADRC) at the University of Washington (UW) that was initiated in July 2003. The initial four Specific Aims of the PANDA NP Group are unchanged from our previous applications: (i) provide diagnostic expertise, (ii) facilitate research, (iii) teach and mentor trainees, and (iv) develop innovative approaches. Two new Specific Aims have been added in this application that are focused on Targeted Molecular Testing (TMT): (v) quantify targeted cerebrospinal fluid (CSF) biomarkers in the UW ADRC CSF Bank that derives in large part from the OHSU ADC and UW ADRC Clinical Cores, and (vi) provide targeted genetic testing relevant to AD and related neurodegenerative diseases. All of our activities are focused on enhancing the research value of tissue and body fluid donations from cognitively healthy individuals and patients with neurodegenerative diseases while insuring proper safeguards.
AD is a looming public health disaster for US citizens, both patients and caregivers, and our health care system. There Is no effective treatment for AD. This application is a response to the need to deepen our understanding of AD so effective treatments can be developed.
|Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20|
|Toledo, Jon B; Gopal, Pallavi; Raible, Kevin et al. (2016) Pathological Î±-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathol 131:393-409|
|Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90|
|Brenowitz, Willa D; Hubbard, Rebecca A; Keene, C Dirk et al. (2016) Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement :|
|Besser, Lilah M; Alosco, Michael L; Ramirez Gomez, Liliana et al. (2016) Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. J Neuropathol Exp Neurol 75:955-962|
|Crane, Paul K; Gibbons, Laura E; McCurry, Susan M et al. (2016) Importance of home study visit capacity in dementia studies. Alzheimers Dement 12:419-26|
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2016) Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr 65:231-8|
|Beckelman, Brenna C; Zhou, Xueyan; Keene, C Dirk et al. (2016) Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease. Neurodegener Dis 16:39-43|
|Henderson, Benjamin W; Gentry, Erik G; Rush, Travis et al. (2016) Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-Î² levels in brain. J Neurochem 138:525-31|
|Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93|
Showing the most recent 10 out of 583 publications